A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Leiden University Medical Center
Fudan University
Takeda
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Tianjin Medical University Cancer Institute and Hospital
Brown University
University of Rochester
Ohio State University Comprehensive Cancer Center
St Vincent's Hospital, Sydney
M.D. Anderson Cancer Center